BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 23356031)

  • 1. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
    Deps P; Guerra P; Nasser S; Simon M
    Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report.
    Silva IM; Oliveira CA; Guedes WR; Oliveira BB; Oliveira DA; Guedes Filho G
    Braz J Infect Dis; 2009 Apr; 13(2):158-60. PubMed ID: 20140364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
    Lockwood DN; Cunha Mda G
    Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical and hematological side effects of clofazimine in leprosy patients.
    Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
    Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
    Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
    Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
    Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
    Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
    Lim JT; Tan T
    Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
    Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].
    Goulart IM; Arbex GL; Carneiro MH; Rodrigues MS; Gadia R
    Rev Soc Bras Med Trop; 2002; 35(5):453-60. PubMed ID: 12621663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy.
    Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA
    Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251
    [No Abstract]   [Full Text] [Related]  

  • 16. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
    Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
    Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug therapy (MDT) and leprosy control.
    Noordeen SK
    Indian J Lepr; 1990; 62(4):448-58. PubMed ID: 2086680
    [No Abstract]   [Full Text] [Related]  

  • 18. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
    Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
    Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population--Curupaiti State Hospital, Rio de Janeiro, Brazil.
    Andrade VL; Marques AB; da Cunha LH; Avelleira JR
    Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):435-40. PubMed ID: 3655459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
    Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.